What is the recommended treatment for ophthalmic herpes zoster (shingles)?

Treatment of Herpes Zoster Ophthalmicus (Shingles Ophthalmicus)

Start oral antiviral therapy immediately—preferably within 72 hours of rash onset—with valacyclovir 1000 mg three times daily for 7 days or famciclovir 500 mg three times daily for 7 days; these are superior to acyclovir and should be the first-line agents. 1

Acute Treatment Algorithm

First-Line Oral Antivirals (Choose One)

The most recent ophthalmology guidelines provide clear dosing for varicella zoster virus (VZV) conjunctivitis/ophthalmicus:

• Valacyclovir: 1000 mg every 8 hours for 7 days 1
• Famciclovir: 500 mg three times daily for 7 days 1
• Acyclovir: 800 mg five times daily for 7 days (less preferred due to inferior pharmacokinetics) 1

Why valacyclovir or famciclovir over acyclovir? A 2012 systematic review of high-quality RCTs demonstrated that valacyclovir reduced herpes zoster-associated pain by 36% at 21-30 days (NNT=3), while famciclovir reduced pain risk by 46% at 28-30 days (NNT=3), both significantly outperforming acyclovir 2. Their superior bioavailability, longer half-life, and simpler dosing (3x daily vs 5x daily) make them clearly preferable 2, 3.

Topical Therapy Considerations

Topical antivirals alone are NOT effective for VZV ophthalmicus 1, 4. However:

• Topical antibiotics: Use prophylactically to prevent secondary bacterial infection of vesicles, which can cause severe conjunctival scarring and even cicatricial ectropion 1
• Topical corticosteroids: Reserved for stromal keratitis or uveitis complications, but ONLY in conjunction with systemic antivirals—never use steroids alone 1

Critical Timing

The 72-hour window is crucial. Antivirals are most effective in preventing ocular complications when initiated within 72 hours of rash onset 5. However, treatment should still be started even if presenting later, particularly if new lesions are still forming or if ocular involvement is present 6.

Ophthalmology Referral

Urgent ophthalmology consultation is mandatory when any of the following are present 7, 6:

• Hutchinson's sign (vesicles on tip/side of nose—indicates nasociliary nerve involvement)
• Any visual symptoms (pain, photophobia, decreased vision, red eye)
• Suspected keratitis, uveitis, or other intraocular involvement
• Periorbital involvement

Approximately 50% of HZO patients develop ocular disease, and up to 25% develop chronic or recurrent disease 7.

Chronic/Recurrent Disease Management

Suppressive Therapy

For patients with persistent or recalcitrant disease, chronic sequelae, or recurrent episodes 1:

• Continue oral antivirals with dose adjustment based on clinical response
• Consider long-term prophylaxis in patients with multiple recurrences
• Recent evidence from the 2025 ZEDS trial: While the primary endpoint at 12 months didn't reach statistical significance (HR 0.77, p=0.09), suppressive valacyclovir 1000 mg daily for 12 months showed benefit at 18 months (HR 0.73, p=0.03) and reduced multiple episodes of keratitis/iritis at both timepoints 8. This supports consideration of 1 year of suppressive therapy for HZO.

Immunocompromised Patients

May require more aggressive treatment with higher doses or prolonged duration 1. Always adjust dosing for renal impairment 1.

Prevention: Vaccination

Strongly recommend recombinant zoster vaccine (RZV/Shingrix) for all patients ≥50 years old 4. RZV is vastly superior to the older live-attenuated vaccine (ZVL):

• Efficacy: 96% vs 70% for preventing HZ 4
• HZO prevention: 67-93% effective 3
• Safe for immunocompromised patients (unlike ZVL which is contraindicated) 9
• Two-dose series required 4

Even patients with prior HZO should be vaccinated, as recurrence risk is approximately 10% within 1 year 10.

Common Pitfalls to Avoid

1. Don't wait for ophthalmology before starting antivirals—begin immediately and refer concurrently
2. Don't use topical antivirals alone—they are ineffective for VZV 1
3. Don't use topical steroids without systemic antivirals—this can worsen viral replication
4. Don't forget renal dosing adjustments—all three antivirals require dose reduction in renal impairment 1
5. Don't dismiss patients >72 hours from rash onset—still treat if active disease or ocular involvement present

Late Sequelae Monitoring

Patients require long-term follow-up for 1:

• Dry eye syndrome
• Corneal anesthesia with neurotrophic keratitis
• Post-herpetic neuralgia (affects up to 20% of HZO patients) 11
• Chronic or recurrent keratitis/uveitis
• Secondary glaucoma